Objective. To provide an overview of the known pharmacological activity of the solvent for pacli taxel, Cremophor, and the implications for therapy with paclitaxel.
Data Sources. Following an outline of the chemistry of Cremophor and its potential to cause hypersensitivity, we present a summary of our own results from studies on the effect of Cremophor as an MDR modulator.
Data Extraction. The pharmacokinetic inter actions of paclitaxel and Cremophor are discussed, with reference to our own preclinical and clinical studies of Cremophor, and literature reports of altered drug disposition following combination therapy with paclitaxel are examined.
Data Synthesis. Cremophor is not an inert solubiliser. Cremophor may contribute to drug interactions by altering drug disposition, and it has the ability to modulate multidrug resistance. As a consequence of the presence of Cremophor in the paclitaxel formulation, the use of paclitaxel should be considered as the administration of two agents.
Basf.Cremophor EL. [Technical Leaflet.]Ludwigshafen, Germany: BASF Bioresearch; 1988;MEF074e.
2.
Lorenz W., Reimann H-J., Dormann P., et al. Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions.1977;7:63-67.
3.
Besarab A., Jarrell BE, Hirsch S., et al. Use of the isolated perfused rat kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, Cremophor EL . Transplantation.1987;44: 195-201.
4.
Roman ID, Monte MJ, Estellier A., Jimenez R.Cholestasis in the rat by means of intravenous administration of cyclosporin vehicle, Cremophor EL. Transplantation.1989 ;48:554-558.
5.
Weiss RB, Donehower RC, Wiemik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol.1990;8:1263-1268.
6.
Eisenhauer EA , ten Bokkel Huinink WW, Swenerton kDa, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low dose and long versus short infusion. J Clin Oncol.1994;12:2654-2666.
7.
Nolte H., Carstensen H., Hertz H.VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatric Hematol Oncol.1988;10:308-312.
8.
Friedland D. , Gorman G., Treat J.Hypersensitivity reactions from taxol and etoposide. J Natl Cancer Inst.1993;85:2036.
9.
Burke MJ, Siegel D., Davidow B.Anaphylaxis: consequence of yew (Taxus) needle ingestion. NY State J Med.1979;79:1576-1578.
Borst P., Schinkel AH, Smit JJ, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther.1993;60:289-299.
13.
Woodcock DM , Jefferson S., Linsenmeyer ME, et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res.1990; 50:4199-4203.
14.
Woodcock DM , Linsenmeyer ME, Chojnowski G., et al. Reversal of multidrug resistance by surfactants. Br J Cancer.1992;66:62-68.
15.
Friche E., Jensen PB, Sehested M., et al. The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun.1990 ;2:297-303.
16.
Schuurhuis GJ, Broxterman HJ, Pinedo HM, et al. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer.1990;62:591-594.
17.
Dudeja PK, Anderson KM, Harris JS, et al. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys.1995;319:309-315.
18.
Fisher GA, Sikic BIClinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am.1995;9:363-382.
19.
Ferry DR, Traunecker H., Kerr DJClinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer.1996;32A:1070-1081.
20.
Rischin D., Millward M., Webster L., et al. Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs.1994;5(Suppl. 1):43.
21.
Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of CremophorEL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst. 1993;85: 1685-1690.
22.
Rischin D., Webster LK, Millward MJ, et al. Cremophor pharmacokinetics in patients receiving 3, 6 and 24 hour infusions of paclitaxel. J Natl Cancer Inst.1996;88:1297-1301.
23.
Calvert AH, Boddy A., Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions . Semin Oncol.1995;22(Suppl 12):91-98.
24.
O'Shaughnessy JA, Fisherman JS, Cowan KHCombination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol.1994;21:19-23.
25.
Rowinsky EK , Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol.1991;9:1692-1703.
26.
Gianni L., Munzone E., Capri G., et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-fmding and sequence-finding study. J Clin Oncol.1995;13:2688-2699.
27.
Ellis AG, Crinis NA, Webster LKInhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol.1996;38:81-87.
28.
Webster LK, Ellis AGEffect of Cremophor EL on elimination of paclitaxel by the isolated perfused rat liver. Proc Aust Soc Clin ExpPharmacol Ther.1995;2:71.
29.
Gianni L., Kearns C., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol.1995;13:180-190.
30.
Sonnichsen DS , Relling MVClinical pharmacokinetics of paclitaxel. Clin Pharmacokinet.1994;27:256-269.
31.
Sparreboom A. , van Tellingen O., Nooijen WJ, Beijnen JHNonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res.1996;56:2112-2115.
32.
Webster LK, Cosson EJ, Stokes KH, Millward MJEffect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer.1996;73: 522-524.
33.
Colombo T., Zucchetti M., D'Incalci M.Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther.1994;269:22-27.
34.
Sridhar R., Dwivedi C., Anderson J., et al. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst.1992;84: 1653-1660.
35.
Keller RP, Altermatt HJ, Donatsch P., et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide enhance in vivo cytostatic activity and toxicity. Int J Cancer.1992;51:433-438.
36.
Bartlett NL , Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol.1994;12:835-842.
37.
Kerr DJ, Graham J., Cummings J., et al. The effect of verapamil on the pharmacokinetics of Adriamycin . Cancer Chemother Pharmacol.1986;18:239-242.
38.
Rushing DA, Raber SR, Rodvold KA, et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer.1994;74:834-841.
39.
Lum BL, Kaubisch S., Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol.1992;10:1635-1642.
40.
Speeg KV, Maldonado ALEffect of cyclosporine on colchicine partitioning in the rat liver. Cancer Chemother Pharmacol.1993; 32:434-436.
41.
Watanabe T. , Miyauchi S., Sawada Y., et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol.1992;16:77-88.
42.
Woodburn K. , Kessel D.The alteration of plasma lipoproteins by Cremophor EL. J Photochem Photobiol.1994;22:197-201.
43.
Sykes E., Woodburn K., Decker D., Kessel D.Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer.1994;70:401- 404.
44.
Kessel D., Woodburn K., Decker D., Sykes E.Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol Res.1995;7:207-212.
45.
Fjallskog M-L. , Frii L., Bergh J.Paclitaxel-induced cytotoxicity—the effects of Cremophor EL on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein . Eur J Cancer.1994;30A: 687-690. [Erratum: Eur J Cancer1994;30A:896.]
46.
Csoka K., Dhar S., Fridborg H., Larsson R., Nygren P.Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer.1997;79:1225-1233.
47.
Chervinsky DS, Brecher ML, Hoelcle MJCremophor EL enhances Taxol efficacy in a multidrug resistant C1300 neuroblastoma cell line. Anticancer Res.1993;13:93-96.
48.
Nygren P., Csoka K., Jonsson B., et al. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer.1995;71:478-481.
49.
Liebmann JE , Cook JA, Lipschultz C., et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer.1993 ;68:1104-1109.
50.
Liebmann JE , Cook JA, Lipschultz C., et al. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol.1994;33: 331-339.
51.
Bertoncello I., Kriegler AB, Woodcock DM, et al. Haematopoietic radioprotection by Cremophor: a polyethoxylated castor oil. Int J Radiat Biol.1995;67:57-64.
